ArticleScientific reports2025
Anticandidal activity of greenly synthesized silver nanoparticles formulated using Alkanna tinctoria roots against multidrug resistant candidal pathogens.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Kombucha-Mediated Silver Nanoparticles with Fungicidal Activity Against WHO-PriorityCurrent issues in molecular biology · 2026Article
- The Antimicrobial and Cytotoxic Activity of Green-Synthesized Silver Nanoparticle Extract of Marine Bacteria and Their 16S rRNA Identification and Characterization.Bioinorganic chemistry and applications · 2026Article
- Plant-Mediated Fabrication of Silver Nanoparticles UsingBioinorganic chemistry and applications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Multidrug-resistant Candida infections demand urgent therapeutic solutions. This study demonstrated the green synthesis of silver nanoparticles designated At-AgNPs using Alkanna tinctoria root extract, showing enhanced antifungal activity against Candida species including resistant C. auris. Characterization confirmed spherical At-AgNPs with 19.91 nm diameter by TEM and 120.6 nm hydrodynamic size, exhibiting a UV-Vis peak at 406.27 nm. EDX analysis revealed 79.24% silver content, while XRD patterns verified face-centered cubic crystallinity. The nanoparticles maintained excellent stability with zeta potential measuring - 23.34 mV and PDI 0.202. At-AgNPs displayed strong antifungal effects, particularly against C. parapsilosis showing 15.46 mm inhibition zone with MIC and MFC values of 1.0 and 2.0 mg/L respectively. Notable synergy emerged when combining At-AgNPs with conventional antifungals, especially clotrimazole against C. albicans demonstrating 37.28 mm inhibition compared to 33.84 mm for clotrimazole alone. SEM imaging revealed extensive morphological damage to fungal cells following combination treatment. These results position At-AgNPs as a viable adjunct therapy capable of boosting conventional treatment effectiveness while potentially lowering required drug doses and minimizing side effects in resistant Candida infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.